Polyrizon emerges with positive preclinical data on nasal protection platform

The company demonstrated strong mucoadhesion and broad surface coverage in ex vivo nasal tissue models raanana, israel, may 21, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the “company” or “polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform.
PLRZ Ratings Summary
PLRZ Quant Ranking